NCT05936632

Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

Preferences of Individuals in the United States With Personal Experience of Cancer for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 998 (actual)
• Sponsor: London School of Economics and Political Science · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients. It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit. This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs. To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.

Conditions

• Cancer

Interventions

Type	Name	Description
OTHER	Discrete Choice Experiment (DCE)	DCE survey experiment

Timeline

• Start date: 2023-07-07
• Primary completion: 2023-07-20
• Completion: 2023-07-20
• First posted: 2023-07-10
• Last updated: 2024-06-11

Locations

1 site across 1 country: United Kingdom